Comparative efficacy of the newer nucleosides (fludarabine, 2'-deoxycoformycin, and 2-chlorodeoxyadenosine) in the treatment of indolent lymphoid malignancies.
Saven
A
A
Clinical Drug Development Program, Ida M. and Cecil H. Green Cancer Center, Scripps Clinic and Research Foundation, La Jolla, CA 92037.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017338:Cladribine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D015394:Molecular Structure; D015649:Pentostatin / Q000627:therapeutic use; D011684:Purine Nucleosides / Q000627:therapeutic use*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D011684:Purine Nucleosides; D015649:Pentostatin; D017338:Cladribine; D014740:Vidarabine; C024352:fludarabine